If one in two of us will develop cancer in our lifetime (Cancer Research UK, 2023), then survivorship is no longer a specialist issue - it is everyone’s business. Cancer is increasingly becoming a long-term condition rather than an acute episode of care. Advances in population-level screening, earlier detection, and increasingly effective multimodal and targeted treatments have transformed cancer into a condition that many people now live with or beyond for extended periods of time. At present, around 3 million people in the United Kingdom (UK) are currently living with or beyond cancer (East of England Cancer Alliance, 2026). 

For many people, surviving cancer does not equate to a return to their pre-diagnosis health. Instead, a substantial proportion live with new physical or psychological symptoms that arise months or years after completion of treatment known as late effects, and/ or long-term effects, which are treatment-related toxicities that begin during therapy but persist indefinitely (Stein et al, 2020). While half of people with cancer may now live for more than 10 years after their diagnosis, Macmillan Cancer Support (2013) estimate that at least 625,000 people in the UK suffer from chronic medical conditions caused by their cancer or its treatment (Harrington et al, 2017). 

Although anyone treated for cancer may experience late or long-term effects of cancer treatment, the risk is not evenly distributed, but influenced by factors including age, pre-existing co-morbidities, frailty, cancer type, treatment modality, and cumulative treatment exposure. These effects include cardiotoxicity, lymphedema, peripheral neuropathy, endocrine dysfunction, dental issues, chronic fatigue, cognitive impairment, psychological distress, and sexual dysfunction (Gegechkori et al, 2018), affecting employment, relationships, independence, and quality of life (QOL). 

Despite their prevalence, late and long-term effects remain under-recognised and inconsistently managed across the National Health Service (NHS) as historically, cancer services have been conceptualised and commissioned as an acute-episode pathway designed around diagnosis, curative or palliative treatment, and surveillance for recurrence. However, the contemporary epidemiology of cancer, characterised by prolonged survivorship, multimorbidity, and chronic treatment-related toxicity, means the challenge extends beyond survivorship provision. It demands a workforce equipped to recognise and manage late effects, cross-sector capability that supports integrated care across services, and patient-safety infrastructure designed for a population living with cancer as a long-term condition. 

Most people living with or beyond cancer spend most of their lives outside specialist oncology services, with ongoing care delivered by general practice nurses, district nurses, community teams, allied health professionals, and care-home staff. Yet, many of these professionals receive little or no formal education in recognising or managing the long-term consequences of cancer treatment (Lash et al, 2024). Non-specific symptoms such as fatigue, cognitive decline, or pain are often isolated without historical context or misattributed to other comorbidities. This has significant consequences for patients and the wider system. When late effects are interpreted as new pathology, those living with and beyond cancer often undergo unnecessary investigations, imaging, invasive procedures, and specialist referrals, that add to burden without addressing the underlying cause. Care becomes fragmented as patients are passed across specialities and the duplication of services is costly, delays intervention, and increases the risk of avoidable harm or reduced QOL. 

This exposes an important policy gap. National strategies rightly prioritise earlier diagnosis, faster treatment, and improved survival, but comparatively little attention has been given to life after treatment. The NHS Long Term Plan (2019) and National Cancer Plan (2026) position survivorship as a core priority, committing to personalised cancer care, and recognising the importance of Holistic Needs Assessments, treatment summaries, and stratified follow-up, yet implementation remains uneven and largely process-driven. These challenges are exacerbated by the current NHS cancer-care climate, in which rising incidence, increasing treatment complexity, and sustained workforce shortages place significant pressure on both oncology and generalist services alike. 

Against this backdrop, the publication of the new NHS Leadership and Management Framework (2026) is particularly timely and aligns closely with the ACCEND programme and similar frameworks in devolved nations such as the Northern Ireland Cancer Nursing Competency Framework. They all reveal the same principle, that leadership is a universal professional responsibility, rather than the responsibility of only those in formal managerial roles. For cancer nurses, it is a mandate to influence beyond specialist oncology services. 

This means advocating for education that equips all nurses and allied HCPs to recognise late and long-term effects, shaping integrated pathways that connect specialist, primary, community, and emergency care, ensuring treatment summaries and personalised cancer care plans are meaningful, timely, and accessible. Furthermore, using quality-improvement approaches to reduce unwarranted variation in follow-up and championing equitable access to survivorship support for underserved populations. Late and long-term effects must become a core component of under- and postgraduate education across all disciplines. Risk-stratified follow up should be consistently implemented and supported by clear referral pathways. Outcomes should move beyond survival alone to include QOL, functional recovery, and the burden of treatment-related morbidity. 

As the cancer landscape continues to evolve, we must also guard against a growing tendency within policy and public discourse to become consumed by solely survival metrics. Improved survival is unquestionably a success, but it is not an indicator of whether care is genuinely serving patients long-term wellbeing. We must ensure outcomes are impressive not only in numerical terms but in lived experience. Cancer nursing has always been rooted in the principle of adding life to days, not simply days to life, and survivorship demands that we hold tightly to this ethos. Cancer nurse leadership means recognising that the end of treatment is not the end of need. For patients, ringing the bell should mark the end of treatment – not the end of support. If cancer care is to be truly patient centred, we must ensure that no one celebrating the end of treatment is left standing at the edge of the survivorship cliff.